Blinatumomab Biosimilar - Research Grade

Mancusi et al. Blinatumomab Redirects Donor Lymphocytes against CD19+ Acute Lymphoblastic Leukemia without Relevant Bystander Alloreactivity after Haploidentical Hematopoietic Stem Cell Transplantation. Int. J. Mol. Sci, 2023, 24(22), 16105

Human

CD3 + CD19

>1mg/ml

ScFv-His

https://www.imgt.org/mAb-DB/

ICH3002

P07766;P15391

Blue ice

ICH5025 is an unconjugated, non-therapeutic recombinant analog of blinatumomab, supplied strictly for research use. Blinatumomab is a bispecific T-cell engager (BiTE) built as a single polypeptide that fuses two single-chain variable fragments: one arm engaging CD19 on B-lineage cells and the other engaging CD3 on T cells, bridging the two to redirect polyclonal T-cell cytotoxicity onto CD19-positive targets. This RUO analog reproduces that dual-specificity, single-chain format (here expressed as an ScFv-His construct for convenient purification and detection), making it a practical tool for in-vitro T-cell redirection assays, target-binding and cross-linking studies, bispecific-engager assay development, and as a positive control or benchmark reference alongside novel BiTE or CAR constructs. It is offered at low endotoxin (research grade less than 1 EU/mg; ultra-low less than 0.5 EU/mg) and in bulk milligram-to-gram quantities suitable for standardized, reproducible preclinical work. It is not the clinical product and is not intended for human or veterinary use, diagnosis, or therapy. CD19 (UniProt P15391) is a B-lineage transmembrane glycoprotein of the immunoglobulin superfamily expressed from early pro-B through mature B cells but lost on terminally differentiated plasma cells. As a component of the CD19/CD21/CD81 co-receptor complex, it lowers the threshold for B-cell receptor signaling and is a defining marker of normal and malignant B cells, including most B-cell acute lymphoblastic leukemias. CD3 epsilon (UniProt P07766) is an invariant subunit of the CD3 signaling module that, with the CD3 gamma, delta and zeta chains, assembles with the alpha/beta T-cell receptor. CD3 transduces antigen-recognition signals into T-cell activation via ITAM phosphorylation. By simultaneously binding CD19 and CD3, a BiTE forms a cytolytic synapse independent of TCR specificity or MHC, triggering perforin/granzyme-mediated killing of the CD19-positive cell.

T-cell surface antigen T3/Leu-4 epsilon chain, B-lymphocyte surface antigen B4, Differentiation antigen CD19, T-cell surface antigen Leu-12, T-cell surface glycoprotein CD3 epsilon chain, B-lymphocyte antigen CD19, CD3E, T3E, CD19

Detects human CD3/CD19. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Blinatumomab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Blinatumomab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Blinatumomab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Blinatumomab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Blinatumomab that binds human CD3 + CD19.